Condition: Diabetes Mellitus, Type 2 · Surgical Site Infection · Sponsor: Abraham Hulst, MD, PhD
A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol/L, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.
This description comes directly from the study's public registry record.
Ayla Y. Stobbe, MD · 0031205669111 · a.y.stobbe@amsterdamumc.nl
Sarah E. Siegelaar, MD, PhD · 0031205669111 · s.e.siegelaar@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06638567